Shenzhen Weiguang Biological Products Co Ltd (002880) — Net Asset Quality Index
Shenzhen Weiguang Biological Products Co Ltd (002880) has a Net Asset Quality Index of 67.5% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.67 Billion minus total liabilities of CN¥1.19 Billion yields net assets of CN¥2.48 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Shenzhen Weiguang Biological Products Co total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shenzhen Weiguang Biological Products Co Ltd Net Asset Quality Index Over Time (2012–2025)
This chart shows how Shenzhen Weiguang Biological Products Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 67.5%, representing net assets of CN¥2.48 Billion against total assets of CN¥3.67 Billion CNY. For live market cap and overall valuation, see Shenzhen Weiguang Biological Products Co market capitalisation.
Annual Net Asset Quality Index for Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check strategic asset allocation of Shenzhen Weiguang Biological Products Co to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.4% | CN¥2.45 Billion | CN¥3.74 Billion | CN¥1.29 Billion | ▼ -2.7 pp |
| 2024 | 68.1% | CN¥2.24 Billion | CN¥3.30 Billion | CN¥1.05 Billion | ▼ -3.0 pp |
| 2023 | 71.1% | CN¥2.05 Billion | CN¥2.88 Billion | CN¥831.14 Million | ▼ -1.4 pp |
| 2022 | 72.5% | CN¥1.87 Billion | CN¥2.58 Billion | CN¥708.20 Million | ▼ -16.8 pp |
| 2021 | 89.3% | CN¥1.79 Billion | CN¥2.00 Billion | CN¥215.23 Million | ▲ +0.8 pp |
| 2020 | 88.4% | CN¥1.62 Billion | CN¥1.84 Billion | CN¥212.36 Million | ▼ -2.9 pp |
| 2019 | 91.4% | CN¥1.45 Billion | CN¥1.59 Billion | CN¥136.64 Million | ▲ +1.9 pp |
| 2018 | 89.5% | CN¥1.31 Billion | CN¥1.46 Billion | CN¥153.53 Million | ▲ +2.0 pp |
| 2017 | 87.5% | CN¥1.20 Billion | CN¥1.37 Billion | CN¥171.52 Million | ▲ +31.9 pp |
| 2016 | 55.7% | CN¥506.44 Million | CN¥909.88 Million | CN¥403.44 Million | ▲ +9.7 pp |
| 2015 | 46.0% | CN¥393.71 Million | CN¥855.97 Million | CN¥462.25 Million | ▲ +5.9 pp |
| 2014 | 40.1% | CN¥308.86 Million | CN¥769.59 Million | CN¥460.73 Million | ▲ +8.7 pp |
| 2013 | 31.4% | CN¥223.88 Million | CN¥712.79 Million | CN¥488.91 Million | ▲ +11.1 pp |
| 2012 | 20.3% | CN¥135.00 Million | CN¥665.63 Million | CN¥530.63 Million | — |